862 results on '"Rosenblat, Joshua D"'
Search Results
2. Assessing the Effects of Metabolic Disruption, Body Mass Index and Inflammation on Depressive Symptoms in Post-COVID-19 Condition: A Randomized Controlled Trial on Vortioxetine
3. Impact of vortioxetine on psychosocial functioning moderated by symptoms of fatigue in post-COVID-19 condition: a secondary analysis
4. Impact of Elevated Body Mass Index (BMI) on Hedonic Tone in Persons with Post-COVID-19 Condition: A Secondary Analysis
5. Dextromethorphan-Bupropion for the Treatment of Depression: A Systematic Review of Efficacy and Safety in Clinical Trials
6. Depression, anxiety and post-traumatic stress during the 2022 Russo-Ukrainian war, a comparison between populations in Poland, Ukraine, and Taiwan
7. Number needed to treat (NNT) for ketamine and esketamine in adults with treatment-resistant depression: A systematic review and meta-analysis
8. Effects of anhedonia on health-related quality of life and functional outcomes in major depressive disorder: A systematic review and meta-analysis
9. Spectral signatures of psilocybin, lysergic acid diethylamide (LSD) and ketamine in healthy volunteers and persons with major depressive disorder and treatment-resistant depression: A systematic review
10. Comparing suicide completion rates in bipolar I versus bipolar II disorder: A systematic review and meta-analysis
11. Impact of vortioxetine on depressive symptoms moderated by symptoms of anxiety in persons with post-COVID-19 condition: A secondary analysis
12. The association between ketamine and esketamine with alcohol and substance misuse: Reports to the Food and Drug Administration adverse event reporting system (FAERS)
13. Protocols and practices in psilocybin assisted psychotherapy for depression: A systematic review
14. A comparison between psilocybin and esketamine in treatment-resistant depression using number needed to treat (NNT): A systematic review
15. Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin
16. The rapid antidepressant effectiveness of repeated dose of intravenous ketamine and intranasal esketamine: A post-hoc analysis of pooled real-world data
17. Association of SARS-CoV-2 infection with neurological impairments in pediatric population: A systematic review
18. Psilocybin-assisted therapy for depression: A systematic review and meta-analysis
19. Clinical efficacy and safety of Zuranolone (SAGE-217) in individuals with major depressive disorder
20. Peripheral inflammatory biomarkers define biotypes of bipolar depression
21. Evaluating the Use of Glucagon-Like Peptide 1 for the Treatment of Cognitive Dysfunction in Individuals with Mood Disorders
22. Engaging Mood Brain Circuits with Psilocybin (EMBRACE): a study protocol for a randomized, placebo-controlled and delayed-start, neuroimaging trial in depression
23. Impacts of metabolic disruption, body mass index and inflammation on cognitive function in post-COVID-19 condition: a randomized controlled trial on vortioxetine
24. Predicting outcome with Intranasal Esketamine treatment: A machine-learning, three-month study in Treatment-Resistant Depression (ESK-LEARNING)
25. Association between fatigue and depressive symptoms in persons with post-COVID-19 condition: a post hoc analysis
26. Association between dual orexin receptor antagonists (DORAs) and suicidality: reports to the united states food and drug administration adverse event reporting system (FAERS)
27. Risk of VMAT2 inhibitors on suicidality and parkinsonism: report utilizing the United States Food and Drug Administration adverse event reporting system
28. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 Update on Clinical Guidelines for Management of Major Depressive Disorder in Adults: Réseau canadien pour les traitements de l'humeur et de l'anxiété (CANMAT) 2023 : Mise à jour des lignes directrices cliniques pour la prise en charge du trouble dépressif majeur chez les adultes
29. COVID-19 vaccination for the prevention and treatment of long COVID: A systematic review and meta-analysis
30. Real world effectiveness of repeated ketamine infusions for treatment-resistant depression with comorbid borderline personality disorder
31. Association of a low protein diet with depressive symptoms and poor health-related quality of life in CKD
32. A Research Domain Criteria (RDoC)-Guided Dashboard to Review Psilocybin Target Domains: A Systematic Review
33. Lumateperone for the Treatment of Adults With Schizophrenia: a Systematic Review
34. Evaluating the neural substrates of effort-expenditure for reward in adults with major depressive disorder and obesity
35. The therapeutic role of ketamine and esketamine in treating psychopathological domains of depression
36. Evaluating Anhedonia as a risk factor in suicidality: A meta-analysis
37. The effect of ketamine on anhedonia: improvements in dimensions of anticipatory, consummatory, and motivation-related reward deficits
38. Ketamine use in pediatric depression: A systematic review
39. Brain-Derived Neurotrophic Factor (BDNF) as a biomarker of treatment response in patients with Treatment Resistant Depression (TRD): A systematic review & meta-analysis
40. Impact of Elevated Body Mass Index (BMI) on Cognitive Functioning and Inflammation in Persons with Post-COVID-19 Condition: A Secondary Analysis
41. Adjunctive cariprazine for major depressive disorder: a systematic review and meta-analysis
42. Number needed to treat (NNT) for ketamine and esketamine in adults with treatment-resistant depression: A systematic review and meta-analysis
43. The Impact of Cognitive Function on Health-Related Quality of Life in Persons with Post-COVID-19 Condition: A Randomized Controlled Trial on Vortioxetine
44. Brain-derived neurotrophic factor Val66Met and CYP2B6 polymorphisms as predictors for ketamine effectiveness in patients with treatment-resistant depression
45. Real-world effectiveness of ketamine in treatment-resistant depression: A systematic review & meta-analysis
46. The abuse liability of ketamine: A scoping review of preclinical and clinical studies
47. Sex differences in ketamine's therapeutic effects for mood disorders: A systematic review
48. Fatigue and cognitive impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysis
49. Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression
50. Immunity as a Common Risk Pathway for Psychiatric and Medical Comorbidity
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.